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Abstract
The genetic variant rs72824905-G (minor allele) in the PLCG2 gene was previously associated with a reduced Alzheimer’s 
disease risk (AD). The role of PLCG2 in immune system signaling suggests it may also protect against other neurodegenera-
tive diseases and possibly associates with longevity. We studied the effect of the rs72824905-G on seven neurodegenerative 
diseases and longevity, using 53,627 patients, 3,516 long-lived individuals and 149,290 study-matched controls. We rep-
licated the association of rs72824905-G with reduced AD risk and we found an association with reduced risk of dementia 
with Lewy bodies (DLB) and frontotemporal dementia (FTD). We did not find evidence for an effect on Parkinson’s disease 
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s0040 1-019-02026 -8) contains 
supplementary material, which is available to authorized users.
Extended author information available on the last page of the article
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(PD), amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS) risks, despite adequate sample sizes. Conversely, 
the rs72824905-G allele was associated with increased likelihood of longevity. By-proxy analyses in the UK Biobank sup-
ported the associations with both dementia and longevity. Concluding, rs72824905-G has a protective effect against multiple 
neurodegenerative diseases indicating shared aspects of disease etiology. Our findings merit studying the PLCγ2 pathway 
as drug-target.
Keywords Alzheimer’s disease · Frontotemporal dementia · Dementia with Lewy bodies · Progressive supranuclear palsy · 
Parkinson’s disease · Amyotrophic lateral sclerosis · Multiple sclerosis · Neurodegenerative disease · Longevity · PLCG2 · 
Phospholipase C Gamma 2
Introduction
The protein product of the phospholipase Cγ2 (PLCG2) gene 
is involved in the transmembrane transduction of immune 
signals [30, 42, 45] that determine the fate and function of 
various immune cell types, both in the periphery and the 
brain [42, 45]. It is known that gain-of-function mutations 
in the PLCG2 gene cause autoimmune disorders [40, 46, 
58, 59] and resistance to treatment of chronic lymphocytic 
leukemia [56].
In 2017, a genome-wide association (GWA) study of 
Alzheimer’s disease (AD) showed that the rare nonsyn-
onymous variant in the PLCG2 gene (rs72824905-G; 
p.Pro522Arg; NC_000016.9:g.81942028C > G) reduced 
AD risk (OR = 0.68, p = 5.4 × 10−10) [47]. In both mouse 
and human brain tissues, PLCG2 has been shown to be over-
expressed > 6-log fold in microglia compared to other brain 
cells [12]. Further, PLCG2 has higher expression levels in 
pathologically affected brain regions of AD patients, which 
seems to be driven by microgliosis [7]. Since microglia are 
the brain’s immune cells, these findings suggest an impor-
tant role for PLCG2 in the neural immune response. Next to 
PLCG2, GWA studies of AD identified additional immune- 
and microglia-related genes that associate with AD, e.g. the 
triggering receptor expressed on myeloid cells 2 (TREM2) 
gene and pathway analysis based on these same GWA stud-
ies indicate that the immune system plays a key role in the 
development of AD [47]. Likewise, human genetic studies 
imply the immune system plays a role in other neurodegen-
erative diseases such as frontotemporal dementia (FTD) [3], 
Parkinson’s disease (PD) [13], and multiple sclerosis (MS) 
[17, 20, 41]. We reasoned that next to AD, PLCG2-related 
immune signaling may be involved in the etiology of these 
other neurodegenerative diseases. This led us to question 
whether the rs72824905-G variant in PLCG2 is also associ-
ated with a reduced risk of other neurodegenerative diseases.
Here, we tested whether rs72824905-G protects against 
other neurodegenerative diseases. We first tested whether 
rs72824905-G associates with reduced risk of AD, FTD, 
dementia with Lewy bodies (DLB), progressive supranu-
clear palsy (PSP), PD, amyotrophic lateral sclerosis (ALS) 
and MS. Since a reduced risk of neurodegenerative diseases 
could lead to an increased likelihood to survive to old age, 
we tested whether rs72824905-G associated with longevity.
Materials and methods
Study populations and genotyping
We present a short description of 16 cohorts, often includ-
ing multiple sites or studies, which contributed to this 
manuscript in Suppl. Table 1, Online Resource. Studies 
were approved by corresponding ethics committees and 
informed consent was obtained for all participants (Suppl. 
Table 1, Online Resource). Study characteristics (age, per-
centage female, apolipoprotein E (APOE) status and age) 
are described in Suppl. Table 2, Online Resource. In most 
cohorts, the average age of the controls was lower than that 
of cases (Suppl. Fig 3, Online Resource). We determined 
rs72824905-G genotypes (NC_000016.9:g.81942028C > G, 
p.Pro522Arg) using direct genotyping with a variety of gen-
otyping arrays or TaqMan genotyping. If direct genotyping 
was not available, we used imputation to 1000 Genomes 
phase I version 3 [15] or the Haplotype Reference Consor-
tium (HRC) reference panels [37]. Details on genotyping or 
imputation by study can be found in Suppl. Table 3, Online 
Resource. We studied participants from European descent.
Study populations of AD, FTD, DLB and PSP patients
We compared rs72824905-G genotypes in a total of 4,985 
AD patients and 9,238 controls from eight cohorts. All sam-
ples were independent from Sims et al. [47], but include the 
samples from Conway et al. [7]. We compared in total 2,437 
FTD patients with 10,647 controls from four studies and two 
consortia. Further, we studied 1446 DLB patients with 5509 
controls from five cohorts and 882 PSP patients with 3187 
controls from five cohorts. Details on sample size by cohort 
and which cohort contributed to which analysis can be found 
in Suppl. Table 2, Online Resource.
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Study populations of ALS, PD and MS patients
To study the association of rs72824905-G with ALS, PD and 
MS, we obtained summary statistics from existing GWAS 
meta-analyses, see Suppl. Table 1, 2, 3, Online Resource, 
for study descriptions. We present results of a combined 
total of 28,448 PD patients that were compared with 108,438 
controls: data from 27,595 PD patients and 106,951 con-
trols from the International Parkinson Disease Genomics 
Consortium (IPDGC) [39] were combined with data from 
853 PD patients and 1,487 controls from the Mayo Clinic. 
Furthermore, we studied 10,953 ALS patients and 20,673 
controls, which represents the subset of the data presented 
by van Rheenen et al. [54], for which rs72824905-G was 
imputed with sufficient quality (imputation quality > 0.3). 
Last, we studied 4476 MS patients and 5714 controls which 
were previously described by Dankowski et al. [8].
Study populations of longevity
We investigated the association of rs72824905-G with 
longevity in five different cohorts; in total, we compared 
3516 individuals who reached at least 90 years with 9677 
control individuals who died before age 90 years or were 
last screened before 90 years (Suppl. Table 1–3, Online 
Resource). The data from Tesi et al. [51] were included in 
this study. A subset of 1136 Dutch long-lived individuals 
for whom follow-up data until death were available [22] was 
included. In this subset, we compared the survival of carriers 
of rs72824905-G with non-carriers.
Studies of dementia and longevity by‑proxy 
in the UK Biobank
The UK Biobank is a study of genetic and health of a half 
million people from the United Kingdom [49]. Information 
from parents or first-degree relatives can be used as a proxy-
phenotype for the participants [34]. In this study, we used 
maternal and paternal history of Alzheimer’s/dementia as 
proxy for dementia [34, 36] and the reported age of the par-
ents (at completing the survey or death) as proxy phenotype 
for longevity [44]. In the UK Biobank, the rs72824905-G 
variant was imputed using the available genotyping arrays 
and the HRC-reference panel as previously described [25]. 
The maternal and paternal by-proxy phenotypes were ana-
lyzed separate using the genotypes of the participants and 
the results were meta-analyzed.
We compared rs72824905-G genotypes of 32,262 partici-
pants whose mother was reported to have dementia with the 
genotypes of 346,999 participants whose mothers did not 
have dementia. Likewise, we compared 16,968 participants 
whose father had dementia with 358,468 whose fathers did 
not have dementia.
For the analysis of longevity-by-proxy, we chose the age 
of 90 years as a cut-off for the minimum age reached by 
the parents. By principle, phenotype by-proxy analyses suf-
fer from dilution effect [34, 36]; therefore, a more extreme 
parental age cut-off of 95 years was also studied. In this 
analysis, we compared 35,256 UK Biobank participants who 
had a mother who reached at least 90 years (7790 moth-
ers reached the age of 95 years) with 342,810 participants 
whose mother did not reach 90 years of age. Likewise, we 
compared 17,558 UK Biobank participants with a father 
who reached at least 90 years (3,043 fathers reached the age 
of 95 years) with 353,100 participants whose father did not 
reach 90 years of age.
Statistical analysis
R (version 3.5.1) was used for all analysis [50]. Logistic 
regression models were fitted within studies to assess the 
association of rs72824905-G with AD, FTD, DLB, and PSP 
patients, and long-lived individuals, compared to controls. 
For each study, we calculated the odds ratio’s (OR) and 
95% confidence intervals (CI). We accounted for popula-
tion substructure by adjusting for principal components or 
by comparing cases and controls from the same study or 
country of origin. We meta-analyzed the effect estimates 
(log(OR)) from the studies using inverse-variance fixed-
effect meta-analyses (R-package ‘rmeta’ v3.0). The fraction 
of variance that is due to heterogeneity was estimated by 
the  I2 statistic [21]. We visualized survival of rs72824905-
G carriers compared to non-carriers using Kaplan–Meier 
curves. Differences in survival were tested using a Cox pro-
portional hazards model correcting for (age at inclusion, sex 
and relatedness).
For MS, the results originate from a single study, which 
used ancestry principal components (PCs) to adjust for 
population stratification [8]. The statistical methods of 
the GWAS meta-analyses of ALS and PD were previously 
described [39, 54]. In short, individual cohorts calculated 
logistic regression models and then summary statistics of 
cohorts were combined using inverse-variance fixed-effect 
meta-analyses. PCs were used to adjust for population strati-
fication. Analysis in the UK Biobank were performed using 
logistic regression models adjusted for genotyping array and 
the first 12 PCs. Effect estimates of the paternal and mater-
nal analysis were combined using inverse-variance fixed-
effect meta-analysis (R-package ‘rmeta’ v3.0). We reported 
two-sided p values and considered p values < 0.05 as signifi-
cant; p values are not corrected for multiple testing.
Power analysis
For all diseases studied, we performed power analysis using 
the online tool Genetic Association Study (GAS) power 
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Calculator implementing the methods described in Skol 
et al. [48]. We calculated power of our analysis to attain a p 
value of 0.05 and used the total number of cases and controls 
from our analysis. We assumed an additive model, a minor 
allele frequency of 0.009 and a disease frequency of 0.01 
for all diseases (higher disease frequency assumption would 
lead to higher power estimates). We report the power for an 
OR between 1 and 2. This corresponds to protective OR (the 
inverse OR = 1/OR) between 0.50 and 1.
Results
An overview of study sample, contributing studies, cor-
rections applied by study and counts of carriers split by 
case–control status is shown in Table 1.
Association with brain diseases
We replicated the association of rs72824905-G in PLCG2 
with a reduced AD risk (OR = 0.57, p = 6.0 × 10−4, I2 = 0%). 
In addition, we found that rs72824905-G associated with a 
reduced risk of both DLB (OR = 0.54, p = 0.045, I2 = 0%) 
and FTD (OR = 0.61, p = 0.011, I2 = 0%). In contrast, we 
found no evidence that rs72824905-G is associated with 
PSP (OR = 1.46, p = 0.19, I2 = 0%), ALS (OR = 1.07, 
p = 0.52, I2 = 0%), PD (OR = 1.18, p = 0.10, I2 = 0) and MS 
(OR = 0.99, p = 0.95). The association of rs72824905-G 
with these seven brain diseases is shown in Fig. 1. In Suppl. 
Figs. 2–7, Online Resource, we show the association esti-
mates for each study separately in the meta-analyses for AD, 
DLB, FTD, PSP, ALS and PD (the MS study consisted of 
a single study).
Association with longevity
In line with a reduced risk of neurodegenerative diseases, 
we found that rs72824905-G associated with a 1.49 (95% 
CI 1.12–1.98) increased likelihood (p = 6.3 × 10−3, I2 = 0%) 
to reach the age of 90  years. Although no heterogene-
ity was observed between studies, it is of interest that a 
cohort of centenarians who were selected based on being 
100 years old and cognitively healthy (description of ‘100-
plus Study’ in Suppl. Table 1, Online Resource) was most 
enriched with rs72824905-G (OR = 2.36, 95% CI 1.34–4.15, 
p = 2.8 × 10−3) (Suppl. Fig 8, Online Resource). Next, we 
tested whether carrying the rs72824905-G variant was 
associated with longer survival after the age of 90 years in 
1,136 Dutch long-lived individuals of which 96.3% were 
followed until death [median age at inclusion 93.2, IQR 
91.6–95.0 years, 63% female; mean survival after inclusion 
was 3.3 years; inter quartile range (IQR) 1.4–5.8 years]. 
We found that 28 carriers survived a median of 4.7 years 
(IQR = 1.9–7.4) while 1108 non-carriers survived a median 
of 3.3 years (IQR = 1.4–5.8) (Suppl. Fig 9, Online Resource). 
However, the difference was not significant (HR 0.75, 95% 
CI 0.51–1.09, p = 0.078), likely due to the low number of 
rs72824905-G carriers in the analysis, as a consequence of 
variant rareness (MAF ~ 1%).
Association with by‑proxy dementia and longevity
In line with the protection against AD, the by-proxy analy-
sis showed that PLCG2 variant carriers had a reduced risk 
of having a parent with dementia, OR = 0.88 (0.81–0.95, 
p = 1.9 × 10−3) (Fig. 2). Next, we tested the association of 
rs72824905-G with longevity-by-proxy. Carriers of the 
rs72824905-G variant did not have an increased likelihood 
of having a parent who reached 90 years of age compared 
to non-carriers (OR = 1.05, p = 0.24). However, carriers 
did have an increased likelihood of having a parent who 
reached 95 years (OR = 1.19, p = 2.1 × 10−2). The threshold 
of 95 years was chosen as too few parents reached the age 
of 100 years.
Power analysis
Power analysis (Suppl. Fig 10, Online Resource) showed 
that the PD, MS and ALS analysis had adequate statisti-
cal power (power > 0.8) to detect a protective association 
(p = 0.05) with an OR ~ 0.68 (the OR for AD reported in 
Sims et al. [47].). The PSP analysis had the lowest statistical 
power (0.32 at the expected OR = 0.67).
Discussion
A recent study showed the protective effect against AD risk 
of the p.Pro552Arg nonsynonymous amino acid change in 
PLCG2 (rs72824905-G) [47]. We replicated this protective 
effect in independent AD patients and controls. Addition-
ally, we found that the variant also protected against FTD 
and DLB, but not against ALS, PD and MS. The analysis 
of PSP was inconclusive because of insufficient power. We 
also found that rs72824905-G associated with increased 
likelihood of longevity, which is according to expectations, 
since overall dementia is the leading cause of death at older 
age [1]. Indeed, the strongest effect of PLCG2 variant was 
observed in cognitively healthy centenarians, individuals 
where an absence of dementia and extreme longevity is com-
bined. Our findings were supported by analyses of by-proxy 
phenotypes for dementia and longevity in the UK Biobank. 
Taken together, the association of the rs72824905-G variant 
with a decreased risk of multiple dementia types and the 
increased risk of longevity warrants thorough investigation 
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Table 1  Study sample description
Consortium or combined cohort name corresponds to the name used in the figures of this manuscript. Studies/sites included or reference to 
cohort shows the studies combined to form one site (if more then one). Additional information on studies included can be found in supplemen-
tary Table 2. If studies/sites include a reference, the exact methods described in the reference were used to obtain the genotypes and association 
results
AD Alzheimer’s disease, FTD frontotemporal dementia, DLB dementia with Lewy bodies, PSP progressive supranuclear palsy, PD Parkinson’s 
Disease, ALS Amyotrophic Lateral Sclerosis, MS multiple sclerosis, MAF Minor allele frequency, ADC Amsterdam Dementia Cohort, NBB 
Netherlands Brain Bank, LASA Longitudinal Aging Study Amsterdam, GEHA Genetics of Healthy Ageing Study, NL, AgeCoDe German Study 
on Ageing, Cognition and Dementia in Primary Care Patients, GBC Gothenburg Birth Cohort Studies, IFGC International FTD-Genomics Con-
sortium, IPDGC The International Parkinson Disease Genomics Consortium, KKNMS German Competence Network Multiple Sclerosis, LLS 
Leiden Longevity study, RiMoD-FTD Risk and modifying factors in Frontotemporal Dementia, UCLA/UCSF Genetic Investigation in Fronto-
temporal Dementia and Alzheimer’s Disease (GIFT) Study
a The number of carriers and minor allele frequency were calculated in a subset of 21092 cases and 23896 controls. No combined estimate of 
Trait Consortium or combined 
cohort name
Studies/sites included Corrections Cases Controls
N N-carriers MAF N N-carriers MAF
AD Amsterdam UMC ADC, NBB, LASA PC1-3 1893 24 0.63 2571 64 1.24
Brain compendium Keogh et al. [29] None 277 0 0 362 6 0.83
Mayo Clinic Conway et al. [7] None 1477 19 0.64 1487 29 0.98
NDRU cohort NDRU cohort None 527 7 0.66 343 8 1.17
Spanish cohorts Valdecilla Cohort, Fundació ACE, 
Oviedo, Sant Pau (SPIN cohort), San 
Sebastian
None 23 0 0 746 10 0.67
Swedish studies GBC Studies, Clinical AD cohort 
sweden.
None 564 6 0.53 3480 61 0.88
UCLA/UCSF GIFT Chen et al. [6] None 224 0 0 249 10 2.01
Combined AD 4985 56 0.56 9238 188 1.02
DLB Amsterdam UMC ADC, NBB, LASA PC1-3 189 2 0.53 2571 64 1.24
Brain compendium Keogh et al. [29] None 97 1 0.52 362 6 0.83
Mayo Clinic Conway et al. [7] None 306 2 0.33 1487 29 0.98
NDRU cohort NDRU cohort None 622 8 0.64 343 8 1.17
Spanish cohorts Valdecilla Cohort, Fundació ACE, 
Oviedo, Sant Pau (SPIN cohort), San 
Sebastian
None 232 3 0.65 746 10 0.67
Combined DLB 1446 16 0.55 5509 117 1.06
FTD Amsterdam UMC ADC, NBB, LASA PC1-3 231 1 0.22 2571 64 1.24
Brain compendium Keogh et al. [29] None 93 2 1.08 362 6 0.83
IFGC Ferrari et al. [11] None 1360 22 0.81 5059 118 1.17
RiMoD-FTD (Consortium) None 255 3 0.59 1660 38 1.17
Spanish cohorts Valdecilla Cohort, Fundació ACE, 
Oviedo, Sant Pau (SPIN cohort), San 
Sebastian
None 366 1 0.14 746 10 0.67
UCLA/UCSF GIFT Chen et al. [6] None 132 2 0.76 249 10 2.01
Combined FTD 2437 31 0.64 10,647 246 1.19
PSP Brain compendium Keogh et al. [29] None 17 1 2.94 362 6 0.83
Mayo Clinic Conway et al. [7] None 231 9 1.95 1487 29 0.98
NDRU cohort NDRU cohort None 613 11 0.9 343 8 1.17
UCLA/UCSF GIFT Chen et al. [6] None 12 0 0 249 10 2.01
Combined PSP 873 21 1.20 2441 53 1.09
PD IPDGC Nalls et al. [39] ≥3PCs 27,595 340a 0.81a 106,951 391a 0.81a
Mayo Clinic Conway et al. [7] None 853 18 1.06 1487 29 0.98
MS KKNMS Dankowski et al. [3] PC1 and 2 4476 82 0.92 5714 107 0.94
ALS Project MinE Van Rheenen et al. [8] PC1-4 10,953 214 0.98 20,673 385 0.93
longevity AgeCoDe AgeCoDe None 462 14 1.52 861 19 1.12
Amsterdam UMC 100-Plus Study, LASA, NBB PC1-3 293 16 2.73 2571 64 1.24
Danish studies Multiple Danish studies None 853 10 0.59 2793 33 0.59
Leiden Longevity Study LLS, GEHA-NL None 1138 28 1.23 743 11 0.74
GBC Studies GBC Studies None 770 16 1.04 2709 45 0.83
Combined longevity 3516 84 1.19 9677 172 0.89
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of the molecular mechanisms underlying this protective 
effect.
Thus far, the common APOE ɛ4 allele and the rare 
TREM2.R47H variant are strong genetic risk factors shared 
across AD, FTD and DLB (not TREM2 [55]). [2, 11, 18, 27, 
47] The HLA-locus and the microtubule-associated protein 
tau (MAPT) loci (not individual variants) also have (sug-
gestive) effects on the risks of AD, FTD and DLB [3, 11, 
18, 43]. The APOE gene has been implied in a multitude of 
pathways [52], TREM2 and HLA are involved in immunity 
[2], and MAPT encodes the tau protein. These shared genetic 
risk factors indicate a partial overlap in AD, DLB and FTD 
etiology. It is of interest that, like the PLCG2 variant, APOE 
and the HLA-DR locus were also associated with longev-
ity [4, 10, 28, 38]. A possible explanation is that APOE, 
PLCG2 and HLA are involved in the processing of accumu-
lated aging-associated proteins [9]. In line with this hypoth-
esis, rs72824905-G is associated with reduced  pTau181 in the 
CSF of memory clinic patients with pathologic Aβ1-42 CSF 
levels (L. Kleineidam et al. submitted). It is well known that 
having a dementia-associated neurodegenerative disease is 
associated with shorter life-span [57]. Conversely, resilience 
to diseases is associated with a longer life-span [24]. It is 
likely that the association of rs72824905-G with longevity 
is due to the protection against dementia-associated neuro-
degenerative diseases. However, with the available data we 
cannot exclude that rs72824905-G has an independent effect 
of rs72824905-G on the risk of longevity and/or the risk 
of maintaining cognitive health. In line with this observa-
tion, we anecdote one cognitively healthy centenarian who 
is homozygous for the APOE ɛ4 risk allele, but also car-
ried the rs72824905-G allele. On MRI scan and amyloid 
scan (PiB-PET), this person has some global atrophy and 
only amyloid-β positivity in the precuneus and in the frontal 
lobes (Fig. 3). At the age of 90 years, the dementia risk for 
homozygous carriers of the APOE ɛ4 genotype is approxi-
mately 80% [53] and virtually all are amyloid positive by age 
90 [26]. The literature reports only a handful of centenarians 
who are homozygous for the APOE ɛ4 allele [14, 16, 23]. 
It is unknown if these individuals were cognitively healthy. 
This case shows that cognitively healthy aging in the pres-
ence of the APOE ɛ4ɛ4 genotype is possible, likely due to 
the protective effect of other genetic variants, such as the 
rs72824905-G variant in PLCG2 [26, 53].
The mechanism that explains the protective effect of 
rs72824905-G variant in the PLCG2 gene is currently 
unclear. We find that the associations of the rs72824905-G 
variant with disease risk differ between diseases that have 
overlapping pathological features. For example, we observe 
that carrying the rs72824905-G variant is protective against 
DLB, but not against PD, while a common characteristic for 
both diseases is the presence of α-synuclein-positive Lewy 
MAF can be given
Table 1  (continued)
Fig. 1  Association results of rs72824905-G with seven brain diseases and longevity. *P values < 0.05. Numbers (N) of cases (patients or long-
lived individuals) and controls studied. The figure shows the odds-ratio (box) of the rs72824905-G with the 95% confidence intervals (whiskers)
Fig. 2  Association results of rs72824905-G with dementia by-proxy and longevity by-proxy analysis in the UK Biobank. *P values < 0.05. The 
figure shows the odds-ratio (box) of the rs72824905-G with the 95% confidence intervals (whiskers)
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bodies. The same holds for pathologies associated with the 
FTD-ALS and PSP spectrum of diseases (e.g. TDP-43, FUS 
inclusions as well as aggregations of tau). The observation 
that our results do not point to a single pathological condi-
tion does not preclude that PLCG2 is involved in a single 
biological process. In fact, determining the involvement of 
the PLCG2-related pathway might be an asset in pathologi-
cal classifications of diseases, e.g. differentiating between 
DLB and PD. Thus far, only one publication investigated 
the functional effect of the rs72824905-G variant in in vitro 
experiments [35]. The authors suggest that in the mouse 
and human brain, PLCɣ2 is expressed in microglia [12]. 
They show that PLCɣ2 mRNA co-localized with microglia-
specific markers in healthy brain tissue and is expressed in 
microglia near amyloid-β plaques in an APP mouse model 
[35]. Furthermore, functional characterization of PLCɣ2 
with the p.Pro552Arg amino acid substitution suggested only 
a slight increase in activity compared to wild-type PLCɣ2 
[35]. While additional functional experiments will be needed 
to confirm these findings, these experiments suggest that 
the functional changes induced by the PLCɣ2 p.Pro552Arg 
genetic variant may be subtle and, therefore, difficult to pin-
point. This is according to expectations, as major changes 
to the immune system will most likely be harmful. Indeed, 
known germline mutations in PLCG2 cause the immune 
disorders PLAID (PLCG2-associated antibody deficiency 
and immune dysregulation) and APLAID (autoinflammatory 
PLAID) [40, 46, 59] while somatic variants in PLCɣ2 are 
associated with resistance to treatment of leukemia [56] 
(reviewed in Koss et al. [32].). The mutations that cause 
PLAID and APLAID contribute to a strong hyperactivation 
of PLCɣ2 upon activation. In the case of APLAID (caused 
by a p.Ser707Tyr substitution), the auto-inflammation has 
been suggested to be partially driven by PLCɣ2-dependent 
activation of the pyrin (PYD)-domain-containing protein 
3 (NLRP3) inflammasome [5]. The potential of PLCG2 to 
activate the inflammasome is further supported by in vitro 
experiments [31]. The NLRP3 inflammasome is a crucial 
signaling node in microglia that ultimately controls the mat-
uration of pro-inflammatory interleukin (IL)-1β and IL-18 
[19] and has been linked to a multitude of neurodegenerative 
diseases [60]. Although functional studies will need to eluci-
date the effects of the rs72824905-G on PLCɣ2 function, we 
speculate that subtle changes in the NLRP3 inflammasome 
activation may explain its protective effect.
Strengths and weaknesses
The most important strength of our study is that we investi-
gated the effect of the rs72824905-G variant in seven neu-
rological diseases in more than 53,000 patients and almost 
150,000 controls. The AD cases and controls studied here 
were all independent from the AD patients and controls 
in which the protective effect of rs72824905-G was first 
Fig. 3  MRI scan and PiB-PET scan, of a 102-year-old centenar-
ian carrying the homozygote APOE ɛ4 genotype as well as the 
rs72824905-G allele in PLCG2. MRI scan (Titan 3T MR scanner) 
shows some hippocampal atrophy (MTA grade 2), some global corti-
cal atrophy (GCA-scale grade 1), but pronounced posterior cortical 
atrophy (grade 2), moderate white matter hyperintensities (Fazekas 
grade 2), no lacunar infarcts or microbleeds. PET-PiB (scan after 
admission of 396 MBq C-11 PIB, 20-min image starting 90 min after 
administration): Abnormal retention in the posterior cingulate/pre-
cuneus and frontal lobes. Neuropsychological testing around time of 
scanning showed average performance on global cognitive function-
ing/MMSE, memory, attention, working memory, fluency and visuo-
spatial tests compared to the cohort of cognitively healthy centenar-
ians. The result of the clock drawing test is shown. The patient was 
asked to draw a clock and put the time at 10 before 11
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identified [47], but includes the samples used in Conway 
et al. [7] and Tesi et al. [51]. This report offers a robust 
replication of the protection against AD. Some may argue 
that the protective effect observed in FTD and DLB cases is 
driven by misclassified AD cases. However, the effect size of 
rs72824905-G in these cases is very similar to the protective 
effect in AD, which makes it unlikely that the effect can be 
ascribed purely to misclassified AD. Moreover, the age of 
the controls was mostly younger than that of cases, making 
the protection from dementia not a longevity effect.
The large numbers under study were necessary because 
rs72824905-G has a minor allele frequency (MAF) ~ 1% in 
European ancestry populations, which makes it a relatively 
rare genetic variant. Therefore, we ensured that our samples 
provided adequate statistical power to observe a similar pro-
tective effect of rs72824905-G against other neurodegen-
erative diseases. Despite the large sample sizes, we found 
no evidence for this effect in our sample of PD, ALS and 
MS, which makes it unlikely that larger meta-analyses will 
observe an association between rs72824905-G and these 
three diseases. An association of rs72824905-G with an 
increased risk of PSP has been reported previously [7]. In 
our analysis, which includes additional PSP cases, we were 
not able to replicate this finding. Larger studies are needed 
to determine the association with PSP. Including as large as 
possible samples came with the consequence that we were 
not able to correct for population stratification using ances-
try principal components in all studies. Therefore, we used 
PCs were possible and further matching cases and controls 
by study or country of origin. Finally, we indicate that the 
identified effects need to be replicated in other ethnicities in 
which rs72824905-G occurs. We note that in some ethnicities 
rs72824905-G plays no role as the frequency is very low in 
African (MAF = 0.0012) and African-American populations 
(MAF = 0.0004), and is not observed in East Asian [7, 33].
Conclusions
Our study shows that the rs72824905-G allele in PLCG2 
associates with a decreased risk for AD, FTD, DLB and 
concurrently with an increased chance of longevity. The pro-
tective effect of the rs72824905-G allele was not observed 
in ALS, PD and MS cases, which suggests that PLCG2-
associated processes overlap in the etiology of AD, FTD 
and DLB, but not in the etiologies of ALS, PD and MS 
(PSP too little power). Explaining the protective effect of the 
PLCγ2 protein on brain immune function may contribute to 
the design of successful therapeutic intervention strategies 
applicable to those at risk for neurodegenerative diseases.
Acknowledgements The following studies and consortia have contrib-
uted to this manuscript. Amsterdam dementia Cohort (ADC): Research 
of the Alzheimer center Amsterdam is part of the neurodegeneration 
research program of Amsterdam Neuroscience. The Alzheimer Center 
Amsterdam is supported by Stichting Alzheimer Nederland and Sticht-
ing VUmc fonds. The clinical database structure was developed with 
funding from Stichting Dioraphte. Genotyping of the Dutch case-con-
trol samples was performed in the context of EADB (European Alz-
heimer DNA biobank) funded by the JPco-fuND FP-829-029 (ZonMW 
projectnumber 733051061). 100-Plus study: We are grateful for the 
collaborative efforts of all participating centenarians and their family 
members and/or relations. This work was supported by Stichting Alz-
heimer Nederland (WE09.2014-03), Stichting Diorapthe, horstingstuit 
foundation, Memorabel (ZonMW projectnumber 733050814) and 
Stichting VUmc Fonds. Genotyping of the 100-Plus Study was per-
formed in the context of EADB (European Alzheimer DNA biobank) 
funded by the JPco-fuND FP-829-029 (ZonMW projectnumber 
733051061). German Study on Ageing, Cognition and Dementia in 
Primary Care Patients (AgeCoDe): This study/publication is part of the 
German Research Network on Dementia (KND), the German Research 
Network on Degenerative Dementia (KNDD; German Study on Age-
ing, Cognition and Dementia in Primary Care Patients; AgeCoDe), and 
the Health Service Research Initiative (Study on Needs, health service 
use, costs and health-related quality of life in a large sample of oldest-
old primary care patients (85+; AgeQualiDe)) and was funded by the 
German Federal Ministry of Education and Research (grants KND: 
01GI0102, 01GI0420, 01GI0422, 01GI0423, 01GI0429, 01GI0431, 
01GI0433, 01GI0434; grants KNDD: 01GI0710, 01GI0711, 01GI0712, 
01GI0713, 01GI0714, 01GI0715, 01GI0716; grants Health Service 
Research Initiative: 01GY1322A, 01GY1322B, 01GY1322C, 
01GY1322D, 01GY1322E, 01GY1322F, 01GY1322G). Alfredo Ram-
irez was partly supported by the ADAPTED consortium: Alzheimer’s 
disease Apolipoprotein Pathology for Treatment Elucidation and 
Development, which has received funding from the Innovative Medi-
cines Initiative 2 Joint Undertaking under grant agreement No 115975. 
Brain compendium: This work was funded by the UK Medical 
Research Council (13044). P.F.C. is a Wellcome Trust principal Fellow 
(212219/Z/18/Z)  and a UK NIHR Senior Investigator, who receives 
support from the Medical Research Council Mitochondrial Biology 
Unit (MC_UU_00015/9), and the National Institute for Health Research 
(NIHR) Biomedical Research Centre based at Cambridge University 
Hospitals NHS Foundation Trust and the University of Cambridge. The 
views expressed are those of the author(s) and not necessarily those of 
the NHS, the NIHR, or the Department of Health.Clinical AD, Sweden: 
We would like to thank UCL Genomics for performing the genotyping 
analyses. Danish data: The studies behind the Danish long-lived cases 
received funding from The National Program for Research Infrastruc-
ture 2007 (grant no. 09-063256), the Danish Agency for Science Tech-
nology and Innovation, the Velux Foundation, the US National Institute 
of Health (P01 AG08761), the Danish Agency for Science, Technology 
and Innovation/The Danish Council for Independent Research (grant 
no. 11-107308), the European Union’s Seventh Framework Programme 
(FP7/2007-2011) under grant agreement no. 259679, the INTERREG 
4 A programme Syddanmark-Schleswig-K.E.R.N. (by EU funds from 
the European Regional Development Fund), the CERA Foundation 
(Lyon), the AXA Research Fund, Paris, and The Health Foundation 
(Helsefonden), Copenhagen, Denmark. The GOYA study was con-
ducted as part of the activities of the Danish Obesity Research Centre 
(DanORC, www.danor c.dk) and The MRC centre for Causal Analyses 
in Translational Epidemiology (MRC CAiTE). The genotyping for 
GOYA was funded by the Wellcome Trust (WT 084762). GOYA is a 
nested study within The Danish National Birth Cohort which was 
established with major funding from the Danish National Research 
Foundation. Additional support for this cohort has been obtained from 
the Pharmacy Foundation, the Egmont Foundation, The March of 
Dimes Birth Defects Foundation, the Augustinus Foundation, and the 
Health Foundation. Fundació ACE (FACE): We would like to thank 
patients and controls who participated in this project. We are indebted 
245Acta Neuropathologica (2019) 138:237–250 
1 3
to Trinitat Port-Carbó and her family for their support of Fundació 
ACE research programs. Fundació ACE collaborates with the Centro 
de Investigación Biomédica en Red sobre Enfermedades Neurodegen-
erativas (CIBERNED, Spain) and is one of the participating centers of 
the Dementia Genetics Spanish Consortium (DEGESCO). Agustín 
Ruiz has received support from the EU/EFPIA Innovative Medicines 
Initiative Joint Undertaking ADAPTED Grant No. 115975 and by 
grants PI13/02434 and PI16/01861. Acción Estratégica en Salud, inte-
grated in the Spanish National R + D + I Plan and financed by ISCIII 
(Instituto de Salud Carlos III)-Subdirección General de Evaluación and 
the Fondo Europeo de Desarrollo Regional (FEDER- “Una manera de 
Hacer Europa”), by Fundación bancaria “La Caixa” and Grifols SA 
(GR@ACE project). Genetics of Healthy Ageing Study (GEHA – NL): 
The work described in this paper was funded mainly by the EU GEHA 
Project contract no. LSHM-CT-2004-503-270. Gothenburg Birth 
Cohort (GBC) Studies: We would like to thank UCL Genomics for 
performing the genotyping analyses. The studies were supported by 
The Stena Foundation, The Swedish Research Council (2015-02830, 
2013-8717), The Swedish Research Council for Health, Working Life 
and Wellfare (2013-1202, 2005-0762, 2008-1210, 2013-2300, 2013-
2496, 2013-0475), The Brain Foundation, Sahlgrenska University 
Hospital (ALF), The Alzheimer’s Association (IIRG-03-6168), The 
Alzheimer’s Association Zenith Award (ZEN-01-3151), Eivind och 
Elsa K:son Sylvans Stiftelse, The Swedish Alzheimer Foundation. 
International FTD-Genomics Consortium (IFGC): International FTD-
Genomics Consortium (IFGC): The authors thank the IFGC for provid-
ing relevant data to support the analyses presented in this manuscript. 
Further acknowledgments for IFGC (https ://ifgcs ite.wordp ress.com/), 
e.g. full members list and affiliations, are found in the online supple-
mentary files. IPDGC ( The International Parkinson Disease Genomics 
Consortium): We also would like to thank all members of the Interna-
tional Parkinson Disease Genomics Consortium (IPDGC). See for a 
complete overview of members, acknowledgements and funding http://
pdgen etics .org/partn ers. Kompetenznetz Multiple Sklerose (KKNMS): 
This work was supported by the German Ministry for Education and 
Research (BMBF) as part of the “German Competence Network Mul-
tiple Sclerosis” (KKNMS) (grant nos. 01GI0916 and 01GI0917) and 
the Munich Cluster for Systems Neurology (SyNergy). TA was sup-
ported by the BMBF through the Integrated Network IntegraMent, 
under the auspices of the e:Med Programme (01ZX1614J). BH was 
supported by the EU Horizon 2020 project MultipleMS.Longitudinal 
Aging Study Amsterdam (LASA) is largely supported by a grant from 
the Netherlands Ministry of Health, Welfare and Sports, Directorate of 
Long-Term Care. The authors are grateful to all LASA participants, the 
fieldwork team and all researchers for their ongoing commitment to the 
study. Leiden Longevity Study: This study was supported by a grant 
from the Innovation-Oriented Research Program on Genomics (Sen-
terNovem IGE05007), the Centre for Medical Systems Biology, and 
the Netherlands Consortium for Healthy Ageing (Grant 050-060-810), 
all in the framework of the Netherlands Genomics Initiative/Nether-
lands Organization for Scientific Research (NWO) and by Unilever 
Colworth.Maria Carolina Dalmasso: Georg Forster Research Award 
(Alexander von Humboldt Foundation). Mayo Clinic AD, DLB, PD, 
PSP: We thank the patients and their families for their participation, 
without whom these studies would not have been possible. Funding for 
this work was supported by National Institute on Aging [RF AG051504 
to NET.; U01 AG046139 to NET]; and National Institute of Neurologi-
cal Disorders and Stroke [R01 NS080820 to NET; P50 NS072187]. 
The Mayo Clinic is a Lewy Body Dementia Association (LBDA) 
Research Center of Excellence, American Parkinson Disease Associa-
tion (APDA) Information and Referral Center and Center for Advanced 
Research, NINDS Tau Center without Walls (U54-NS100693) and is 
supported by Mayo Clinic AD and related dementias genetics program, 
The Little Family Foundation, the Mangurian Foundation for Lewy 
body research and NINDS R01 NS078086 (to OAR). The PD program 
at the Mayo Clinic Florida is also supported by the Mayo Clinic Center 
for Regenerative Medicine, Mayo Clinic Center for Individualized 
Medicine, Mayo Clinic Neuroscience Focused Research Team (Cecilia 
and Dan Carmichael Family Foundation, and the James C. and Sarah 
K. Kennedy Fund for Neurodegenerative Disease Research at Mayo 
Clinic in Florida), the gift from Carl Edward Bolch, Jr., and Susan Bass 
Bolch, and The Sol Goldman Charitable Trust. Samples included in 
this study are from the brain bank at Mayo Clinic in Jacksonville which 
is supported by CurePSP|Society for Progressive Supranuclear Palsy 
and the Tau Consortium. NDRU cohort: We would like to thank the 
NIH Neuro Brain Bank for contributing tissue samples; this study was 
supported in part by grants from the National Institutes of Health: 
U19-AG03365, P50 NS38377, and P50-AG005146. Tissue samples for 
genotyping were provided by the Johns Hopkins Morris K. Udall 
Center of Excellence for Parkinson’s Disease Research (NIH P50 
NS38377) and the Johns Hopkins Alzheimer’s Disease Research 
Center. We aregrateful for the support of the entire BIOCARD study 
team at Johns Hopkins University. Additionally, we acknowledge the 
contributions of the Geriatric Psychiatry Branch (GPB) in the intramu-
ral program of NIMH who initiated the BIOCARD study. We would 
like to thank the NIA Baltimore Longitudinal Study of Aging for con-
tributing tissue samples to the Johns Hopkins Alzheimer’s Disease 
Research Center. DNA panels from the NINDS Human Genetics 
Resource Center DNA and Cell Line Repository (http://ccr.corie ll.org/
ninds ) were used in this study, as well as clinical data. We thank the 
following brain banks for providing brain tissues: Banner Sun Health 
Research Institute, New York Brain Bank, Newcastle Brain Tissue 
Resource, Human Brain and Spinal Fluid Resource Center, Netherlands 
Brain Bank Amsterdam, Mount Sinai Brain Bank, Harvard Brain Bank, 
Duke University Brain Bank, Virginia Commonwealth University Brain 
Bank, and the Georgetown University Brain Bank. We also thank the 
following research centers for providing patient samples: University of 
Michigan, University College London Institute of Neurology, Univer-
sity of Maryland, University of California – San Diego, and University 
of Miami. We are grateful to members of the North American Brain 
Expression Consortium for contributing DNA samples. The authors 
thank the patients and families who have donated DNA samples and 
brain tissue for scientific research. The research was supported in part 
by the Intramural Research Program of the NIH National Institute of 
Neurological Disorders and Stroke and the National Institute on Aging 
(project numbers: ZIA-NS003154, Z01-AG000949).” Oviedo: This 
work was partly supported by Grant from Fondo de Investigaciones 
Sanitarias-Fondos FEDER EuropeanUnion to Victoria Alvarez 
PI15/00878. Pascual Sánchez-Juan: Pascual Sánchez-Juan is supported 
by CIBERNED and Carlos III Institute of Health, Spain (PI08/0139, 
PI12/02288, and PI16/01652), jointly funded by Fondo Europeo de 
Desarrollo Regional (FEDER), Unión Europea, “Una manera de hacer 
Europa”. Project MinE: The ProjectMinE study was supported by the 
ALS Foundation Netherlands and the MND association (UK) (Project 
MinE, www.proje ctmin e.com). Risk and modifying factors in Fronto 
Temporal Dementia (RiMoD-FTD): follows: The SPIN cohort: We are 
indebted to patients and their families for their participation in the 
“Sant Pau Initiative on Neurodegeneration cohort”, at the Sant Pau 
Hospital (Barcelona). This is a multimodal research cohort for bio-
marker discovery and validation that is partially funded by Generalitat 
de Catalunya (2017 SGR 547 to JC), as well as from the Institute of 
Health Carlos III-Subdirección General de Evaluación and the Fondo 
Europeo de Desarrollo Regional (FEDER- “Una manera de Hacer 
Europa”) (grants PI11/02526, PI14/01126, and PI17/01019 to JF; 
PI17/01895 to AL), and the Centro de Investigacion Biomedica en Red 
Enfermedades Neurodegenerativas programme (Program 1, Alzheimer 
Disease to AL). We would also like to thank the Fundació Bancària 
Obra Social La Caixa (DABNI project) to JF and AL; and Fundacion 
BBVA (to AL), for their support in funding this follow-up study. San 
Sebastian: We would like to thank patients and control volunteers who 
participated in this study. We thank Ana Gorostidi for his work at the 
Biodonostia HRI Genomics Platform. This work was partly supported 
246 Acta Neuropathologica (2019) 138:237–250
1 3
by CIBERNED. Adolfo López de Munain is supported by Fundación 
Salud 2000 (PI2013156) and Diputación Foral de Gipuzkoa (Exp. 
114/17). UK Biobank analysis: This work was funded by The Nether-
lands Organization for Scientific Research (NWO VICI 453-14-005). 
The analyses were carried out on the Genetic Cluster Computer, which 
is financed by the Netherlands Scientific Organization (NWO: 480-05-
003), by the VU University, Amsterdam, The Netherlands, and by the 
Dutch Brain Foundation, and is hosted by the Dutch National Comput-
ing and Networking Services SurfSARA. This research has been con-
ducted using the UK Biobank resource under application number 
16406. We are grateful to the numerous participants, researchers, and 
staff who collected and contributed to the data.
Data availability statement The authors declare that the data support-
ing the findings of this study are available within the paper and its 
online Resource.
Author contributions SvdL and HH had full access to the meta-anal-
ysis results and wrote the draft of the manuscript. SvdL, OJC, MMC, 
LK, EBvdA, NS, JAC, AZ, TFMA, MD-F, JS-S, HZ, MN, CB, JES, 
JM-F, SM-G, MJK, KB, CL, IdR, WW, BJ, XW, NB, NT, JEC, SLS, 
AK, MCD, MA, NE-T, SWS and Aru analyzed parts of the data. MJTR 
provided compute for this study. MCD compiled demographic informa-
tion of all Spanish cohorts. SvdL, EBvdA, NS, MD-F, JS-S, SM-G, 
CL, IdR, WW, BJ, NB, NT, NE-T, SWS, Aru, IJ, IH, AL, MW, JF, 
IS, MAF, OP, MZ, SR-H, II-G, AO, FTB, MH, CM, BI, MS, EM-R, 
JWI, MNMvB, DA, HW, ERR, BFB, RCP, TJF, JAvG, MJU, LT, WM, 
OD-I, MBo, MB, EM, ALdM, AP, ZKW, OAR, DWD, NRG-R, DK, 
RR, AWL, YALP, PS, TG, PFC, BH, JT, FM, EAN, TIAS, PS-J, DP, 
GC, JC, KC, AR, WMvdF and HH contributed to data collection. JT 
and OP contributed to neuropathological diagnoses. MW, IS, SR-H, 
II-G, MS, HW, LT, WM, MBo, MB, ZKW, AWL, PS, TG, PFC, BH, 
MAH, TIAS, PH, JC, KC, NE-T, SWS, AR, Aru, ES, WMvdF and HH 
secured funding for their respective studies. MMC, MW, SR-H, MH, 
JEC, MS, MNMvB, HW, WM, NMvS, PS, TG, PFC, BH, MAH, EAN, 
PH, NE-T, SWS, AR, ES, WMvdF and HH supervised their respec-
tive studies. HH was responsible for the overall study supervision. All 
authors critically revised the manuscript for important intellectual con-
tent and approved the final manuscript.
Funding statement No funding was received specifically for this study. 
The studies and consortia all have their respective funding sources 
described in the acknowledgement section.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://creat iveco 
mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made.
References
 1. Alzheimer’s A (2016) 2016 Alzheimer’s disease facts and figures. 
Alzheimers Dement 12:459–509
 2. Borroni B, Ferrari F, Galimberti D, Nacmias B, Barone C, Bag-
noli S et al (2014) Heterozygous TREM2 mutations in frontotem-
poral dementia. Neurobiol Aging 35(934):e937-910. https ://doi.
org/10.1016/j.neuro biola ging.2013.09.017
 3. Broce I, Karch CM, Wen N, Fan CC, Wang YP, Tan CH et al 
(2018) Immune-related genetic enrichment in frontotemporal 
dementia: an analysis of genome-wide association studies. Plos 
Med. https ://doi.org/10.1371/journ al.pmed.10024 87
 4. Broer L, Buchman AS, Deelen J, Evans DS, Faul JD, Lunetta KL 
et al (2015) GWAS of longevity in CHARGE consortium confirms 
APOE and FOXO3 candidacy. J Gerontol A Biol Sci Med Sci 
70:110–118. https ://doi.org/10.1093/geron a/glu16 6
 5. Chae JJ, Park YH, Park C, Hwang IY, Hoffmann P, Kehrl JH 
et al (2015) Connecting two pathways through  Ca2+ signaling: 
NLRP3 inflammasome activation induced by a hypermorphic 
PLCG2 mutation. Arthritis Rheumatol 67:563–567. https ://doi.
org/10.1002/art.38961 
 6. Chen JA, Wang Q, Davis-Turak J, Li Y, Karydas AM, Hsu SC 
et al (2015) A multiancestral genome-wide exome array study 
of Alzheimer disease, frontotemporal dementia, and progres-
sive supranuclear palsy. JAMA Neurol 72:414–422. https ://doi.
org/10.1001/jaman eurol .2014.4040
 7. Conway OJ, Carrasquillo MM, Wang X, Bredenberg JM, Reddy 
JS, Strickland SL et al (2018) ABI3 and PLCG2 missense vari-
ants as risk factors for neurodegenerative diseases in Caucasians 
and African Americans. Mol Neurodegener 13:53. https ://doi.
org/10.1186/s1302 4-018-0289-x
 8. Dankowski T, Buck D, Andlauer TF, Antony G, Bayas A, Bech-
mann L et al (2015) Successful replication of GWAS hits for mul-
tiple sclerosis in 10,000 germans using the exome array. Genet 
Epidemiol 39:601–608. https ://doi.org/10.1002/gepi.21933 
 9. Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn MB et al 
(2008) apoE isoform-specific disruption of amyloid beta peptide 
clearance from mouse brain. J Clin Invest 118:4002–4013. https 
://doi.org/10.1172/JCI36 663
 10. Deelen J, Beekman M, Uh HW, Broer L, Ayers KL, Tan Q et al 
(2014) Genome-wide association meta-analysis of human longev-
ity identifies a novel locus conferring survival beyond 90 years of 
age. Hum Mol Genet 23:4420–4432. https ://doi.org/10.1093/hmg/
ddu13 9
 11. Ferrari R, Wang Y, Vandrovcova J, Guelfi S, Witeolar A, Karch 
CM et al (2017) Genetic architecture of sporadic frontotempo-
ral dementia and overlap with Alzheimer’s and Parkinson’s dis-
eases. J Neurol Neurosurg Psychiatry 88:152–164. https ://doi.
org/10.1136/jnnp-2016-31441 1
 12. Friedman BA, Srinivasan K, Ayalon G, Meilandt WJ, Lin H, 
Huntley MA et  al (2018) Diverse brain myeloid expression 
profiles reveal distinct microglial activation states and aspects 
of Alzheimer’s disease not evident in mouse models. Cell Rep 
22:832–847. https ://doi.org/10.1016/j.celre p.2017.12.066
 13. Gagliano SA, Pouget JG, Hardy J, Knight J, Barnes MR, Ryten M 
et al (2016) Genomics implicates adaptive and innate immunity 
in Alzheimer’s and Parkinson’s diseases. Ann Clin Transl Neur 
3:924–933. https ://doi.org/10.1002/acn3.369
 14. Garatachea N, Marin PJ, Santos-Lozano A, Sanchis-Gomar F, 
Emanuele E, Lucia A (2015) The ApoE gene is related with 
exceptional longevity: a systematic review and meta-analysis. 
Rejuvenation Res 18:3–13. https ://doi.org/10.1089/rej.2014.1605
 15. Genomes Project C, Auton A, Brooks LD, Durbin RM, Garrison 
EP, Kang HM, et al (2015) A global reference for human genetic 
variation. Nature 526:68–74. https ://doi.org/10.1038/natur e1539 
3
 16. Gerdes LU, Jeune B, Ranberg KA, Nybo H, Vaupel JW (2000) 
Estimation of apolipoprotein E genotype-specific relative mor-
tality risks from the distribution of genotypes in centenarians 
and middle-aged men: apolipoprotein E gene is a “frailty gene,” 
not a “longevity gene”. Genet Epidemiol 19:202–210. https ://
doi.org/10.1002/1098-2272(20001 0)19:3%3c202 :AID-GEPI2 
%3e3.0.CO;2-Q
 17. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH (2010) 
Mechanisms underlying inflammation in neurodegeneration. Cell 
140:918–934. https ://doi.org/10.1016/j.cell.2010.02.016
 18. Guerreiro R, Ross OA, Kun-Rodrigues C, Hernandez DG, Orme 
T, Eicher JD et al (2018) Investigating the genetic architecture 
247Acta Neuropathologica (2019) 138:237–250 
1 3
of dementia with Lewy bodies: a two-stage genome-wide asso-
ciation study. Lancet Neurol 17:64–74. https ://doi.org/10.1016/
S1474 -4422(17)30400 -3
 19. He Y, Hara H, Nunez G (2016) Mechanism and regulation of 
NLRP3 inflammasome activation. Trends Biochem Sci 41:1012–
1021. https ://doi.org/10.1016/j.tibs.2016.09.002
 20. Hemmer B, Kerschensteiner M, Korn T (2015) Role of the innate 
and adaptive immune responses in the course of multiple scle-
rosis. Lancet Neurol 14:406–419. https ://doi.org/10.1016/S1474 
-4422(14)70305 -9
 21. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a 
meta-analysis. Stat Med 21:1539–1558. https ://doi.org/10.1002/
sim.1186
 22. Holstege H, Beker N, Dijkstra T, Pieterse K, Wemmenhove E, 
Schouten K et al (2018) The 100-plus Study of cognitively healthy 
centenarians: rationale, design and cohort description. Eur J Epi-
demiol. https ://doi.org/10.1007/s1065 4-018-0451-3
 23. Ishioka YL, Gondo Y, Fuku N, Inagaki H, Masui Y, Takayama M 
(2016) Effects of the APOE epsilon4 allele and education on cog-
nitive function in Japanese centenarians. Age (Dordr) 38:495–503. 
https ://doi.org/10.1007/s1135 7-016-9944-8
 24. Ismail K, Nussbaum L, Sebastiani P, Andersen S, Perls T, Bar-
zilai N et al (2016) Compression of morbidity is observed across 
cohorts with exceptional longevity. J Am Geriatr Soc 64:1583–
1591. https ://doi.org/10.1111/jgs.14222 
 25. Jansen IE (2017) Genetic meta-analysis identifies 9 novel loci 
and functional pathways for Alzheimers disease risk. Biorxiv 
1:258533
 26. Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, 
Verhey FRJ et al (2015) Prevalence of cerebral amyloid pathology 
in persons without dementia a meta-analysis. J Am Med Assoc 
313:1924–1938. https ://doi.org/10.1001/jama.2015.4668
 27. Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, 
Snaedal J et al (2013) Variant of TREM2 associated with the risk 
of Alzheimer’s disease. N Engl J Med 368:107–116. https ://doi.
org/10.1056/NEJMo a1211 103
 28. Joshi PK, Pirastu N, Kentistou KA, Fischer K, Hofer E, Schraut 
KE et al (2017) Genome-wide meta-analysis associates HLA-
DQA1/DRB1 and LPA and lifestyle factors with human longevity. 
Nat Commun 8:910. https ://doi.org/10.1038/s4146 7-017-00934 -5
 29. Keogh MJ, Wei W, Wilson I, Coxhead J, Ryan S, Rollinson S 
et al (2017) Genetic compendium of 1511 human brains available 
through the UK Medical Research Council Brain Banks Network 
Resource. Genome Res 27:165–173. https ://doi.org/10.1101/
gr.21060 9.116
 30. Kim D, Jun KS, Lee SB, Kang NG, Min DS, Kim YH et  al 
(1997) Phospholipase C isozymes selectively couple to specific 
neurotransmitter receptors. Nature 389:290–293. https ://doi.
org/10.1038/38508 
 31. Kleineidam L, Chouraki V, Próchnicki T, van der Lee S, Madrid-
Márquez L, Wagner-Thelen H et al (2018) PLCG2 protective vari-
ant p.P522R modulates Tau pathology and disease progression in 
patients with mild cognitive impairment. Lancet. https ://ssrn.com/
abstr act=33076 49
 32. Koss H, Bunney TD, Behjati S, Katan M (2014) Dysfunction 
of phospholipase Cgamma in immune disorders and cancer. 
Trends Biochem Sci 39:603–611. https ://doi.org/10.1016/j.
tibs.2014.09.004
 33. Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fen-
nell T et al (2016) Analysis of protein-coding genetic variation 
in 60,706 humans. Nature 536:285–291. https ://doi.org/10.1038/
natur e1905 7
 34. Liu JZ, Erlich Y, Pickrell JK (2017) Case-control association 
mapping by proxy using family history of disease. Nat Genet 
49:325–331. https ://doi.org/10.1038/ng.3766
 35. Magno L, Lessard CB, Martins M, Lang V, Cruz P, Asi Y et al 
(2019) Alzheimer’s disease phospholipase C-gamma-2 (PLCG2) 
protective variant is a functional hypermorph. Alzheimers Res 
Ther 11:16. https ://doi.org/10.1186/s1319 5-019-0469-0
 36. Marioni RE, Harris SE, Zhang Q, McRae AF, Hagenaars SP, 
Hill WD et al (2018) GWAS on family history of Alzheimer’s 
disease. Transl Psychiatry 8:99. https ://doi.org/10.1038/s4139 
8-018-0150-6
 37. McCarthy S, Das S, Kretzschmar W, Delaneau O, Wood AR, 
Teumer A et al (2016) A reference panel of 64,976 haplotypes 
for genotype imputation. Nat Genet 48:1279–1283. https ://doi.
org/10.1038/ng.3643
 38. McDaid AF, Joshi PK, Porcu E, Komljenovic A, Li H, Sorrentino 
V et al (2017) Bayesian association scan reveals loci associated 
with human lifespan and linked biomarkers. Nat Commun. https 
://doi.org/10.1038/ncomm s1584 2
 39. Nalls MA (2018) Parkinson’s disease genetics: identifying novel 
risk loci, providing causal insights and improving estimates of 
heritable risk. BioRxiv. https ://doi.org/10.1101/38816 5
 40. Ombrello MJ, Remmers EF, Sun G, Freeman AF, Datta S, Torabi-
Parizi P et al (2012) Cold urticaria, immunodeficiency, and auto-
immunity related to PLCG2 deletions. N Engl J Med 366:330–
338. https ://doi.org/10.1056/NEJMo a1102 140
 41. Patsopoulos NA (2018) Genetics of multiple sclerosis: an over-
view and new directions. Cold Spring Harb Perspect Med 8:45. 
https ://doi.org/10.1101/cshpe rspec t.a0289 51
 42. Patterson RL, van Rossum DB, Ford DL, Hurt KJ, Bae SS, Suh 
PG et al (2002) Phospholipase C-gamma is required for agonist-
induced  Ca2+ entry. Cell 111:529–541
 43. Peuralinna T, Myllykangas L, Oinas M, Nalls MA, Keage HA, Iso-
viita VM et al (2015) Genome-wide association study of neocorti-
cal Lewy-related pathology. Ann Clin Transl Neurol 2:920–931. 
https ://doi.org/10.1002/acn3.231
 44. Pilling LC, Kuo CL, Sicinski K, Tamosauskaite J, Kuchel GA, 
Harries LW et al (2017) Human longevity: 25 genetic loci associ-
ated in 389,166 UK biobank participants. Aging (Albany NY) 
9:2504–2520. https ://doi.org/10.18632 /aging .10133 4
 45. Rhee SG (2001) Regulation of phosphoinositide-specific phospho-
lipase C. Annu Rev Biochem 70:281–312. https ://doi.org/10.1146/
annur ev.bioch em.70.1.281
 46. Schade A, Walliser C, Wist M, Haas J, Vatter P, Kraus JM et al 
(2016) Cool-temperature-mediated activation of phospholipase 
C-gamma2 in the human hereditary disease PLAID. Cell Signal 
28:1237–1251. https ://doi.org/10.1016/j.cells ig.2016.05.010
 47. Sims R, van der Lee SJ, Naj AC, Bellenguez C, Badarinarayan 
N, Jakobsdottir J et al (2017) Rare coding variants in PLCG2, 
ABI3, and TREM2 implicate microglial-mediated innate immu-
nity in Alzheimer’s disease. Nat Genet 49:1373–1384. https ://doi.
org/10.1038/ng.3916
 48. Skol AD, Scott LJ, Abecasis GR, Boehnke M (2006) Joint analy-
sis is more efficient than replication-based analysis for two-stage 
genome-wide association studies. Nat Genet 38:209–213. https ://
doi.org/10.1038/ng170 6
 49. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J 
et al (2015) UK biobank: an open access resource for identifying 
the causes of a wide range of complex diseases of middle and 
old age. Plos Med 12:e1001779. https ://doi.org/10.1371/journ 
al.pmed.10017 79
 50. Team RC (2018) R: a language and environment for statistical 
computing. R Foundation for Statistical Computing, Vienna
 51. Tesi N, van der Lee SJ, Hulsman M, Jansen IE, Stringa N, van 
Schoor N et al (2018) Centenarian controls increase variant effect 
sizes by an average twofold in an extreme case-extreme control 
analysis of Alzheimer’s disease. Eur J Hum Genet. https ://doi.
org/10.1038/s4143 1-018-0273-5
248 Acta Neuropathologica (2019) 138:237–250
1 3
 52. Tudorache IF, Trusca VG, Gafencu AV (2017) Apolipoprotein 
E—a multifunctional protein with implications in various patholo-
gies as a result of its structural features. Comput Struct Biotechnol 
J 15:359–365. https ://doi.org/10.1016/j.csbj.2017.05.003
 53. van der Lee SJ, Wolters FJ, Ikram MK, Hofman A, Ikram MA, 
Amin N et al (2018) The effect of APOE and other common 
genetic variants on the onset of Alzheimer’s disease and demen-
tia: a community-based cohort study. Lancet Neurol 17:434–444. 
https ://doi.org/10.1016/S1474 -4422(18)30053 -X
 54. van Rheenen W, Shatunov A, Dekker AM, McLaughlin RL, 
Diekstra FP, Pulit SL et al (2016) Genome-wide association 
analyses identify new risk variants and the genetic architecture 
of amyotrophic lateral sclerosis. Nat Genet 48:1043. https ://doi.
org/10.1038/ng.3622
 55. Walton RL, Soto-Ortolaza AI, Murray ME, Lorenzo-Betancor O, 
Ogaki K, Heckman MG et al (2016) TREM2 p.R47H substitution 
is not associated with dementia with Lewy bodies. Neurol Genet 
2:85. https ://doi.org/10.1212/nxg.00000 00000 00008 5
 56. Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert 
AS et al (2014) Resistance mechanisms for the Bruton’s tyrosine 
kinase inhibitor ibrutinib. N Engl J Med 370:2286–2294. https ://
doi.org/10.1056/NEJMo a1400 029
 57. Xie J, Brayne C, Matthews FE, Medical Research Council Cog-
nitive F, Ageing Study c (2008) Survival times in people with 
dementia: analysis from population based cohort study with 
14 year follow-up. BMJ 336:258–262. https ://doi.org/10.1136/
bmj.39433 .61667 8.25
 58. Yu P, Constien R, Dear N, Katan M, Hanke P, Bunney TD 
et al (2005) Autoimmunity and inflammation due to a gain-of-
function mutation in phospholipase C gamma 2 that specifically 
increases external  Ca2+ entry. Immunity 22:451–465. https ://doi.
org/10.1016/j.immun i.2005.01.016
 59. Zhou Q, Lee GS, Brady J, Datta S, Katan M, Sheikh A et al 
(2012) A hypermorphic missense mutation in PLCG2, encoding 
phospholipase Cgamma2, causes a dominantly inherited autoin-
flammatory disease with immunodeficiency. Am J Hum Genet 
91:713–720. https ://doi.org/10.1016/j.ajhg.2012.08.006
 60. Zhou K, Shi L, Wang Y, Chen S, Zhang J (2016) Recent 
Advances of the NLRP3 Inflammasome in Central Nervous 
System Disorders. J Immunol Res 2016:9238290. https ://doi.
org/10.1155/2016/92382 90
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
Affiliations
Sven J. van der Lee1,2  · Olivia J. Conway3 · Iris Jansen1,4 · Minerva M. Carrasquillo3 · Luca Kleineidam5,6,7 · 
Erik van den Akker8,9 · Isabel Hernández10,11 · Kristel R. van Eijk12 · Najada Stringa13 · Jason A. Chen14 · 
Anna Zettergren15 · Till F. M. Andlauer16,17,18  · Monica Diez‑Fairen19,20 · Javier Simon‑Sanchez21,22 · 
Alberto Lleó11,23 · Henrik Zetterberg24,25,26 · Marianne Nygaard27 · Cornelis Blauwendraat28 · Jeanne E. Savage4 · 
Jonas Mengel‑From29 · Sonia Moreno‑Grau10 · Michael Wagner5,6 · Juan Fortea11,23 · Michael J. Keogh30,31 · 
Kaj Blennow24,25 · Ingmar Skoog15 · Manuel A. Friese18,32 · Olga Pletnikova33 · Miren Zulaica11,34 · 
Carmen Lage11,35,36 · Itziar de Rojas10,11 · Steffi Riedel‑Heller37 · Ignacio Illán‑Gala11,23 · Wei Wei31 · 
Bernard Jeune29 · Adelina Orellana10,11 · Florian Then Bergh18,38 · Xue Wang3 · Marc Hulsman1,2,9 · Nina Beker1 · 
Niccolo Tesi1,2,9  · Christopher M. Morris39 · Begoña Indakoetxea11,34,40 · Lyduine E. Collij41 · Martin Scherer42 · 
Estrella Morenas‑Rodríguez11,23 · James W. Ironside43 · Bart N. M. van Berckel41 · Daniel Alcolea11,23 · 
Heinz Wiendl18,44 · Samantha L. Strickland3 · Pau Pastor19,20 · Eloy Rodríguez Rodríguez11,35,36 · DESGESCO 
(Dementia Genetics Spanish Consortium), EADB (Alzheimer Disease European DNA biobank) · EADB 
(Alzheimer Disease European DNA biobank) · IFGC (International FTD‑Genomics Consortium), IPDGC (The 
International Parkinson Disease Genomics Consortium) · IPDGC (The International Parkinson Disease 
Genomics Consortium) · RiMod‑FTD (Risk and Modifying factors in Fronto‑Temporal Dementia) · Netherlands 
Brain Bank (NBB) · Bradley F. Boeve45 · Ronald C. Petersen45 · Tanis J. Ferman46 · Jay A. van Gerpen47 · 
Marcel J. T. Reinders64 · Ryan J. Uitti47 · Lluís Tárraga10,11 · Wolfgang Maier5,6 · Oriol Dols‑Icardo11,23 · Amit Kawalia7 · 
Maria Carolina Dalmasso7,48 · Mercè Boada10,11 · Uwe K. Zettl18,49 · Natasja M. van Schoor13 · Marian Beekman8 · 
Mariet Allen3 · Eliezer Masliah50 · Adolfo López de Munain11,34,51 · Alexander Pantelyat52 · Zbigniew K. Wszolek47 · 
Owen A. Ross3 · Dennis W. Dickson3 · Neill R. Graff‑Radford47 · David Knopman45 · Rosa Rademakers3 · 
Afina W. Lemstra1 · Yolande A. L. Pijnenburg1 · Philip Scheltens1  · Thomas Gasser53 · Patrick F Chinnery31,54 · 
Bernhard Hemmer17,18,55 · Martijn A. Huisman13,56 · Juan Troncoso33 · Fermin Moreno11,34,40 · Ellen A. Nohr57 · 
Thorkild I. A. Sørensen58,59,60 · Peter Heutink21,22 · Pascual Sánchez‑Juan11,35,36 · Danielle Posthuma2,4 · The GIFT 
(Genetic Investigation in Frontotemporal Dementia and Alzheimer’s Disease) Study Group · Jordi Clarimón11,23 · 
Kaare Christensen27,61,62 · Nilüfer Ertekin‑Taner3,47 · Sonja W. Scholz28,52 · Alfredo Ramirez5,7 · Agustín Ruiz10,11 · 
Eline Slagboom8,63 · Wiesje M. van der Flier1 · Henne Holstege1,2 
 * Sven J. van der Lee 
 s.j.vanderlee@amsterdamumc.nl
 * Henne Holstege 
 h.holstege@amsterdamumc.nl
1 Alzheimer Center Amsterdam, Department of Neurology, 
Amsterdam Neuroscience, Vrije Universiteit Amsterdam, 
Amsterdam UMC, Amsterdam, The Netherlands
2 Department of Clinical Genetics, Vrije Universiteit 
Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands
249Acta Neuropathologica (2019) 138:237–250 
1 3
3 Department of Neuroscience, Mayo Clinic Florida, 
Jacksonville, FL 32224, USA
4 Department of Complex Trait Genetics, Center 
for Neurogenomics and Cognitive Research, Amsterdam 
Neuroscience, Vrije Universiteit Amsterdam, Amsterdam 
UMC, Amsterdam, The Netherlands
5 Department for Neurodegenerative Diseases and Geriatric 
Psychiatry, University of Bonn, Bonn, Germany
6 DZNE, German Center for Neurodegenerative Diseases, 
Bonn, Germany
7 Division of Neurogenetics and Molecular Psychiatry, 
Department of Psychiatry and Psychotherapy, Faculty 
of Medicine, University Hospital Cologne, Cologne, 
Germany
8 Molecular Epidemiology, Leiden University Medical Center, 
Leiden, The Netherlands
9 Pattern Recognition and Bioinformatics, Delft University 
of Technology, Delft, The Netherlands
10 Research Center and Memory Clinic, Fundació ACE, Institut 
Català de Neurociències Aplicades, Universitat Internacional 
de Catalunya, Barcelona, Spain
11 Centro de Investigacion Biomedica en Red en Enfermedades 
Neurodegenerativas (CIBERNED), Madrid, Spain
12 Department of Neurology, Brain Center Rudolf Magnus, 
University Medical Center Utrecht, Utrecht, The Netherlands
13 Amsterdam UMC-Vrije Universiteit Amsterdam, Department 
of Epidemiology and Biostatistics, Amsterdam Public Health 
Research Institute, Amsterdam, The Netherlands
14 Interdepartmental Program in Bioinformatics, University 
of California, Los Angeles, USA
15 Neuropsychiatric Epidemiology Unit, Department 
of Psychiatry and Neurochemistry, Institute of Neuroscience 
and Physiology, Sahlgrenska Academy, Centre for Ageing 
and Health (AgeCap) at the University of Gothenburg, 
Gothenburg, Sweden
16 Max Planck Institute of Psychiatry, Munich, Germany
17 Department of Neurology, Klinikum rechts der Isar, 
Technical University of Munich, Munich, Germany
18 German Competence Network Multiple Sclerosis (KKNMS), 
Munich, Germany
19 Movement Disorders and Memory Unit, Department 
of Neurology, University Hospital Mutua de Terrassa, 
Barcelona, Spain
20 Fundacio per la Recerca Biomedica I Social Mutua Terrassa, 
Terrassa, Barcelona, Spain
21 German Center for Neurodegenerative Diseases 
(DZNE)-Tübingen, Tübingen, Germany
22 Hertie Institute for Clinical Brain Research, University 
of Tübingen, Tübingen, Germany
23 Memory Unit, Department of Neurology, IIB Sant Pau, 
Hospital de la Santa Creu i Sant Pau, Universitat Autonoma 
de Barcelona, Barcelona, Spain
24 Clinical Neurochemistry Laboratory, Sahlgrenska University 
Hospital, Mölndal, Sweden
25 Department of Psychiatry and Neurochemistry, Institute 
of Neuroscience and Physiology, Sahlgrenska Academy 
at the University of Gothenburg, Gothenburg, Sweden
26 Department of Molecular Neuroscience, UCL Institute 
of Neurology, Queen Square, London, UK
27 The Danish Aging Research Center, Epidemiology, 
Biostatistics and Biodemography, Department of Public 
Health, University of Southern Denmark, Odense, Denmark
28 Neurodegenerative Diseases Research Unit, National 
Institute of Neurological Disorders and Stroke, Bethesda, 
MD 20892-3707, USA
29 Epidemiology, Biostatistics and Biodemography, Department 
of Public Health, University of Southern Denmark, Odense, 
Denmark
30 Institute of Genetic Medicine, Newcastle University, 
Newcastle upon Tyne NE1 3BZ, UK
31 Department of Clinical Neurosciences, University 
of Cambridge, Cambridge CB2 0QQ, UK
32 Institut für Neuroimmunologie und Multiple Sklerose 
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